PRESENTATIONS

76 – K Jhaveri et al. Key drivers of therapeutic response and resistance to giredestrant from GO39932: Ph Ia/b study in pts with ER+/HER2- locally advanced or metastatic BC. Poster spotlight at San Antonio Breast Cancer Symposium, 2023.
75 – K Jhaveri et al. Imlunestrant +/- abemaciclib, +/- aromatase inhibitor, in ER+/HER2- advanced BC: updated results from the EMBER study. Oral presentation at San Antonio Breast Cancer Symposium, 2023.
74 – K Jhaveri et al. Exposure–response analyses of GO39932: Ph Ia/b study of giredestrant in ER+/HER2-, locally advanced or metastatic breast cancer. Poster spotlight at San Antonio Breast Cancer Symposium, 2023.
73 – N Turner et al. Capivasertib + CDK4/6i and fulvestrant in pts with HR+/HER2– advanced BC: updated Ph 1b analysis from CAPItello-29. Poster spotlight at San Antonio Breast Cancer Symposium, 2023.
72 – A Collier et al. Circulating tumor DNA dynamics in acelERA: Ph II study of giredestrant for ER+/HER2-, previously treated advanced breast cancer. Poster presentation at San Antonio Breast Cancer Symposium, 2023.
71 – K Jhaveri et al. Imlunestrant with or without everolimus or alpelisib, in ER+/HER2-aBC: Results from the Ph 1a/b EMBER study. Oral presentation at ESMO, Madrid, 2023.
70 – M Martin et al. Characteristics of patients with previously treated, ER+/HER2– advanced BC who had rapid progression in acelERA. Poster presentation at ESMO, Madrid, 2023.
69 – P Neven et al. Capivasertib + palbociclib and fulvestrant in pts with endocrine therapy-resistant HR+/HER2− advanced BC: Ph 1b data from CAPItello-29. Poster presentation at ESMO, Madrid, 2023.
68 – E Lim. Novel Targets and Clinical Trials in Hormone-Related Cancers. Oral presentation at Gordon Conference on Hormone Receptors in Cancer, Maine, 2023.
67 – E Lim et al. Ph I/II study to evaluate the safety and efficacy of vosilasarm (EP0062), an oral Selective Androgen Receptor Modulator, for the treatment of AR+/HER2-/ER+ advanced BC. Poster presentation at ASCO, Chicago, 2023..
66 – A Collier et al. Exploratory biomarker analysis of acelERA Breast Cancer: Ph II study of giredestrant vs. physician’s choice of endocrine therapy for previously treated ER+/HER2– advanced BC. Poster presentation at ASCO, Chicago, 2023.
65 – I Krop et al. Ph III study of TDxD vs TPC in patients with HER2+ mBC previously treated with TDM1: primary results DESTINY-Breast02. Oral presentation at San Antonio Breast Cancer Symposium 2022.
64 – E Lim et al. Ph I/II study to evaluate the safety and efficacy of EP0062 (SARM) for the treatment of AR+HER2-ER+ aBC. Poster presentation at San Antonio Breast Cancer Symposium 2022.
63 – K Jhaveri et al. Imlunestrant in combination with abemaciclib +/- AI in ER+ aBC: Combination tx results from Ph I EMBER study. Poster discussion at San Antonio Breast Cancer Symposium 2022.
62 – T Downton et al. HER2Pro: Ph Ib study of high dose prochlorperazine added to paclitaxel, trastuzumab and pertuzumab in patients with previously untreated HER2+ mBC. Poster presentation at San Antonio Breast Cancer Symposium 2022.
61 – J Chen et al. Stromal mediators of lymphocyte exclusion and dysfunction in TNBC. Poster discussion at San Antonio Breast Cancer Symposium 2022.
60 – A Freelander et al. SARMs + CDK4/6i’s demonstrate anti-cancer activity in preclinical treatment resistant ER+AR+ breast cancer models. Poster presentation at San Antonio Breast Cancer Symposium 2022.
59 – E Lim et al. Exploratory subgroup and biomarker analyses of acelERA, Ph II study of giredestrant vs physician’s choice of endocrine therapy for previously treated, ER+HER2– mBC. Poster discussion at San Antonio Breast Cancer Symposium 2022.
58 – Lim E. Oral Selective Estrogen Receptor Degraders, An emerging therapy for HR+ breast cancer. Invited oral presentation at Asia Pacific Breast Cancer Symposium, Singapore 2022.
57 – Jhaveri K et al. Ph 1a/b trial of imlunestrant, an SERD, in ER+ advanced breast cancer and endometrial endometrioid cancer: Monotherapy results from EMBER Trial. Poster presentation at American Society of Clinical Oncology Conference 2022.
56 – Lim E et al. Ph III ENABLAR-2 study to evaluate enobosarm and abemaciclib compared to endocrine therapy for the 2nd line treatment of AR+ ER+ HER2- MBC in patients who previously received palbociclib and endocrine therapy. Poster presentation at American Society of Clinical Oncology Conference 2022.
55 – Wong K et al. Ph 1 64Cu-SAR-Bombesin PET-CT imaging study in the staging of ER+PR+HER2- metastatic breast cancer. Poster presentation at American Society of Clinical Oncology Conference 2022.
54 – Freelander A et al. Targeting the Androgen Receptor in Endocrine and CDK4/6-inhibitor Resistant Models of ER+ Breast. Poster presentation at San Antonio Breast Cancer Symposium 2021.
53 – Turner N et al. Activity and biomarker analyses from a phase Ia/b study of giredestrant with or without palbociclib in patients with estrogen receptor-positive, HER2-negative locally advanced/metastatic breast cancer. Poster discussion presentation at San Antonio Breast Cancer Symposium 2021.
52 – Wong V et al. Australian real-world outcomes of ribociclib and aromatase inhibitor in metastatic HR+HER2- breast cancer – results from Kisqali Access Registry for Metastatic Breast Cancer in Australia collected alongside a Medicine Access Program. Poster presentation at American Society of Clinical Oncology Conference 2021.
51 – Martin M et al. acelERA. Phase II study evaluating efficacy and safety of Giredestrant vs. physician’s choice of endocrine monotherapy in patients with ER+/ HER2- locally advanced or metastatic breast cancer. Poster presentation at American Society of Clinical Oncology Conference 2021.
50 – Palmieri C et al. Efficacy of enobosarm, a selective AR targeting agent correlates with degree of AR positivity in advanced AR+/ER+ breast cancer in an international Phase 2 clinical study. Poster presentation at American Society of Clinical Oncology Conference 2021.
49 – Moore H et al. Evaluation of pharmacodynamic and biologic activity in a preoperative window-of-opportunity study of giredestrant (GDC-9545) in postmenopausal patients with ER+/HER2– operable breast cancer. Poster presentation at American Society of Clinical Oncology Conference 2021.
48 – Jhaveri K et al. A first-in-human Phase 1a/b trial of LY3484356, an oral SERD in ER+ advanced breast cancer and endometrial endometrioid cancer, Results from the EMBER Study. Poster presentation at American Society of Clinical Oncology Conference 2021.
47 – Palmeiri C et al. Efficacy of Enobosarm, a selective AR targeting agent, in patients with metastatic AR+/ER+ breast cancer resistant to estrogen receptor targeted agents and CDK4/6 inhibitor in a Phase 2 clinical study (Study G200802). Poster presentation at European Society of Medical Oncology Breast Cancer 2021.
46 – Yap YS et al. Efficacy of Enobosarm, a selective AR targeting agent, in patients with metastatic AR+ER+ breast cancer resistant to estrogen receptor targeted agents and CDK 4/6 inhibitor in a Phase II clinical study. Poster presentation at European Society of Medical Oncology Asia 2021.
45 – Lau et al. Winpro: a window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage ER+ breast cancer. San Antonio Breast Cancer Symposium, USA, 2020.
44 – Overmoyer et al. Efficacy and safety of enobosarm, a selective androgen receptor modulator, to target AR in women with advanced ER+/AR+ breast cancer – final results from an international Phase 2 randomized study. San Antonio Breast Cancer Symposium, USA, 2020.
43 – Portman et al. Mdm2 inhibition synergises with endocrine therapy or CDK4/6 inhibition for the treatment of ER+ breast cancer. San Antonio Breast Cancer Symposium, USA, 2020.
42 – Lim E et al. EMBER: A Phase 1a/b trial of LY3484356, a novel, oral selective estrogen-receptor degrader, in advanced ER+ breast cancer and endometroid endometrial cancer. San Antonio Breast Cancer Symposium, USA, 2020.
41 – Lim E et al. The impact of food on tolerability of abemaciclib in patients with previously treated HR+HER2- metastatic breast cancer: An open-label, randomized phase 2 study. Clinical Oncological Society of Australia ASM. 2020.
40 – Lim E et al. Mdm2 inhibition synergises with endocrine therapy or CDK4/6 inhibition for the treatment of ER+ breast cancer. Clinical Oncological Society of Australia ASM. 2020.
39 – Lim et al. A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 +/- palbociclib in ER+ HER2-metastatic breast cancer (selected poster discussion). ASCO, Chicago, USA, 2020.
38 – Lim E. Windows into cancer therapy (invited). Aus India Conference, Adelaide. 2019.
37 – Lim E. et al. The androgen receptor is a tumour suppressor in estrogen receptor positive breast cancer. Oral presentation at San Antonio Breast Cancer Symposium, USA , 2019.
36 – Lim E. et al. The impact of food on tolerability of abemaciclib in patients with previously treated HR+HER2- metastatic breast cancer: An open-label, randomized phase 2 study. Poster presentation at San Antonio Breast Cancer Symposium, USA , 2019.
35 – Lim E. et al. A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with ER+HER2- metastatic breast cancer. Poster presentation at San Antonio Breast Cancer Symposium, USA , 2019.
34 – Lim E. Therapeutic Strategies to Overcome Endocrine Resistance in Breast Cancer. Oral presentation at the China Anti-Cancer Association ASM, Guangzhou, China. 2019.
33 – Lim E. Sex Steroid Receptor Interplay in Breast Cancer. Oral presentation at the China Anti-Cancer Association ASM, Guangzhou, China. 2019.
32 – Lim E. Novel approaches to overcoming endocrine resistance in breast cancer. Oral presentation at the Brisbane Cancer Conference. 2019.
31 – Lim E. CDK4/6 inhibitors, changing the natural history of ER+ breast cancer. Oral presentation at the Adolescent and Young Adult Oncology Symposium, Sydney, 2019.
30 – Swarbrick A, Lim E. Landscape of the breast tumour microenvironment at single-cell resolution. Oral presentation at the San Antonio Breast Cancer Conference USA, 2018.
29 – Wahlroos S, Lim E. Concurrent Exercise and Chemotherapy in Preclinical Breast Cancer Models. Poster presentation at the San Antonio Breast Cancer Conference USA, 2018.
28 – Carson EK, Lim E. The WinPro Study: Endocrine therapy +/- prometrium in postmenopausal women with early stage HR-positive breast cancer. Poster presentation at the San Antonio Breast Cancer Conference USA, 2018.
27 – Chia KM, Lim E. AR activation suppresses growth of ER+AR+ endocrine-resistant breast cancer. Poster presentation at the San Antonio Breast Cancer Conference USA, 2018.
26 – Lim E. A Renaissance in the treatment of endocrine-resistant breast cancer. Oral presentation at the Endocrine Society of Australia ASM. Adelaide. 2018.
25 – Lim E, N Portman, S Alexandrou, S Haupt, Y Haupt, N Caldon. Therapeutic targeting of CDK4/6 inhibitor resistant breast cancer. Poster Presentation at the San Antonio Breast Cancer Conference USA, 2017.
24 – Lim E. Sex Steroid interplay in breast cancer. Oral presentation at WACOG. Perth, 2017.
23 – Lim E. Sensitizing breast cancer to endocrine therapies. Oral Presentation at the TRI symposium on EMT and Cancer. Brisbane, 2017.
22 – Lim E. Steroid Hormone Receptor Interplay and Endocrine Resistance. Oral Presentation at Medical Oncology Group of Australia Annual Scientific Meeting, Melbourne, 2017.
21 – Lim E. Targeting CDKs in Triple Negative Breast Cancer.. Oral Presentation at ANZ Breast Cancer Trialist Group Annual Scientific Meeting, Melbourne, 2017.
20 – Lim E. Translating Biological Insights in ER+ Breast Cancer into Clinical Trials. Oral presentation at the Leura 8 Breast Cancer Conference. NSW. 2016.
19 – Lim E. Modeling resistance to endocrine therapies. Oral presentation at the Clinical Oncological Society of Australia Meeting. Gold Coast. 2016.
18 – Lim E. Translating Biological Insights in ER+ Breast Cancer into Clinical Trials. Oral presentation at the translating molecular insights into clinical practice in breast and prostate cancer Meeting. Cambridge, UK. 2016.
17 – Lim E. Role of extended hormonal therapy and Role of HER2-directed therapies in small tumours. Oral presentation at the Controversies in Breast Cancer Meeting, Barcelona, Spain 2016.
16 – Lim E. Extending CDK inhibitors beyond ER+ Breast Cancer. Oral presentation at the HOTT meeting. Sydney. 2016.
15 – Lim E. Pathological Complete Response as a surrogate endpoint for survival. Oral presentation at the Controversies in Breast Cancer Meeting. Melbourne. 2016.
14 – Lim E. Steroid Receptor Cross Talk in Breast Cancer. Oral Presentation at the Global Breast Cancer Conference, Jeju, S. Korea 2016.
13 – Lim E. New applications for Cyclin Dependent Kinase Inhibitors in Triple Negative Breast Cancer. Oral Presentation at Singapore Breast Cancer Symposium, Cancer Research Institute, National University of Singapore. 2015.
12 – Lim E. Modeling therapeutic resistance in vivo. Oral Presentation at Gordon Conference on Hormone Receptors in Cancer, Maine, USA. 2015.
11 – Lim E. Patient derived breast cancer xenograft models for cancer research. Oral Presentation at Oz Metastases Research Society Symposium, Melbourne, 2014
10 – Lim E. Preclinical insights into steroid receptor signaling in breast cancer. Oral Presentation at ANZ Breast Cancer Trialist Group Annual Scientific Meeting, Wellington, NZ 2014.
9 – Lim E, Cao SA, Brown M, Bailey S. Modeling chemoendocrine therapy for ER+/p53wt luminal breast cancer. Poster Presentation at the San Antonio Breast Cancer Conference USA, 2014.
8 – Chi D, He HH, Yeung TY, Jeselsohn R, Schnitt S, Garber JE, Richardson A, Lim E, Brown M. Differential estrogen receptor signaling in normal mammary epithelial cells, primary breast cancers and metastases. Oral Presentation at the American Association of Cancer Research Annual Meeting, DC, USA. 2013.
7 – Lim E, He HH, Chi D, Yeung TY, Schnitt S, Garber JE, Richardson A, Brown M. Differences in estrogen receptor signaling in non-malignant primary ER-positive breast epithelial cells and breast cancer. Poster Discussion at the San Antonio Breast Cancer Symposium, USA. 2012.
6 – Lim E, He HH, Chi D, Garber JE, Richardson A, Brown M. Estrogen receptor signaling in normal, BRCA1 and BRCA2 mutation associated, and ER-positive breast cancer mammary cells. Poster presentation at the American Society of Clinical Oncology Annual Meeting, Chicago, USA. 2012.
5 – Lim E, He HH, Chi D, Garber JE, Richardson A, Brown M. ER signaling in primary luminal cells from wild type, BRCA1mut, BRCA2mut and ER+ breast cancer. Oral presentation at Dana-Farber/Harvard Cancer Center Women’s Cancer Program ASM. Boston 2012.
4 – Lim E, Wu D, Pal B, Bouras T, Asselin-Labat ML, Vaillant F, Yagita H, Lindeman GJ, Smyth GK, Visvader JE. Transcriptome analyses of mouse and human mammary cell subpopulations reveals multiple conserved genes and pathways. Poster presentation at the San Antonio Breast Cancer Symposium 2010.
3 – Lim E, Vaillant F, Wu D, Forrest N, Pal B, Gyorki D, kConFab, Smyth GK, Visvader JE and Lindeman GJ. Investigation of stem and progenitor subpopulations in human breast tissue from BRCA1 and BRCA2 carriers. Oral presentation at the American Society of Clinical Oncology Annual Meeting, Orlando, USA. 2009.
2 – Lim E, Vaillant F, Forrest N, Pal B, Gyorki D, Partanen A, Thorne H, kConFab, Visvader JE and Lindeman GJ. Investigation of stem and progenitor subpopulations in human breast tissue from BRCA1 and BRCA2 carriers. Oral presentation at Clinical Oncological Society of Australia, Sydney 2008. (Best oral presentation)
1 – Lim E, Vaillant F, Forrest N, Gyorki D, kConFab, Visvader JE and Lindeman GJ. Characterisation of the human breast mammary and cancer stem cell. Oral presentation at Melbourne Health Research week. Melbourne 2008. (Best oral presentation)